United Therapeutics
UTHR
672 hedge funds and large institutions have $12.6B invested in United Therapeutics in 2025 Q2 according to their latest regulatory filings, with 76 funds opening new positions, 284 increasing their positions, 220 reducing their positions, and 71 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 284 | Existing positions reduced: 220
28% more call options, than puts
Call options by funds: $134M | Put options by funds: $105M
7% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 71
0% less funds holding
Funds holding: 674 → 672 (-2)
2.64% less ownership
Funds ownership: 100.12% → 97.48% (-2.6%)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
19% less capital inflows, than outflows
Capital inflows: $1.09B | Capital outflows: $1.35B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$125M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$109M |
| 3 |
Deerfield Management
New York
|
+$79.3M |
| 4 |
AssetMark Inc
Concord,
California
|
+$59M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$44.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$215M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$174M |
| 3 |
Vaughan Nelson Investment Management
Houston,
Texas
|
-$101M |
| 4 |
Avoro Capital Advisors
New York
|
-$91.2M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$47.5M |
UTHR Hedge Fund Activity: Q2 2025 in Review
672 of the 7,623 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q2 2025, worth a combined $12.6B — down 8.8% from $13.9B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new UTHR positions and 71 closed out — a net gain of 5 holders — while 284 added to existing stakes and 220 trimmed.
The largest buyer was Invesco, adding an estimated $125M. The largest seller was Fidelity Investments, cutting an estimated $215M.
- 672 institutional investors held United Therapeutics (UTHR) as of Q2 2025, down from 674 in Q1 2025.
- Funds reported $12.6B of United Therapeutics stock for Q2 2025, down 8.8% quarter-over-quarter.
- 76 funds opened new United Therapeutics positions in Q2 2025 and 71 closed out, a net change of +5 holders.
- The largest United Therapeutics buyer in Q2 2025 was Invesco, an estimated $125M added.
- The largest United Therapeutics seller in Q2 2025 was Fidelity Investments, an estimated $215M sold.
Based on aggregated 13F filings for Q2 2025.